RESEARCH TRIANGLE PARK, N.C. - May 25, 1999 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the formation of Quintiles Allergy and Respiratory Therapeutics to specialize in the development of drugs for allergic and respiratory diseases.
"Quintiles has worked on more than 150 studies involving 50,000 patients suffering from allergies or respiratory diseases," said Ludo Reynders, Chief Executive Officer of Quintiles Product Development group. "Our customers will benefit from the consolidation of the knowledge and experience we have in accelerating the development of drugs to treat allergies and respiratory ailments."
Leading the group is Andre van As, M.D., Ph.D., who has 10 years' experience in the field of allergy and respiratory drug development and 20 years' experience as a principal investigator for a wide variety of respiratory and allergy studies.
"Driving this group's formation is the need for better clinical evaluations of drugs intended for use in allergy and respiratory," Dr. van As said. "Our in-depth expertise in this therapeutic category, combined with our advanced information technology systems, allows us to optimize both quality and speed of product delivery for sponsors."
Quintiles development experience in this therapeutic area includes drugs to treat allergic rhinitis, asthma, chronic obstructive pulmonary disease and acute respiratory distress syndrome. In the United States alone, 40 million to 50 million people have allergies and nearly 14 million suffer from asthma, according to estimates by the American Academy of Allergy, Asthma and Immunology.
As a respiratory clinical research director at Glaxo and Astra Merck, Dr. van As supervised successful clinical development programs and New Drug Application submissions for several asthma and allergy compounds, and strategic development of respiratory marketing and development programs. Prior to entering the pharmaceutical industry, Dr. van As was an academic pulmonologist and chief of the Pulmonary Division at the University of New Mexico.
Quintiles Transnational Corp. is the market leader in providing a full range of integrated product development and commercialization solutions to the pharmaceutical, biotechnology and medical device industries. Quintiles also is a leader in the electronic data interchange and healthcare informatics industry and provides healthcare policy consulting to governments and other organizations worldwide.
Headquartered near Research Triangle Park, North Carolina, Quintiles is a Fortune 1000 company and a member of the Nasdaq-100 Index. With more than 18,000 employees worldwide and offices in 31 countries, Quintiles operates through specialized work groups dedicated to meeting customers' individual needs.